Filtered By:
Condition: Atrial Fibrillation
Countries: Germany Health
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 168 results found since Jan 2013.
Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: insights from a large German claims database
ConclusionBetween 2011 and 2016, the use of guideline-conform antithrombotic therapy in Germany has significantly increased. This was associated with a significant decline in strokes without an increased incidence of bleeding complications.
Source: Clinical Research in Cardiology - February 15, 2019 Category: Cardiology Source Type: research
Syncope in the German Nationwide inpatient sample - Syncope in atrial fibrillation/flutter is related to pulmonary embolism and is accompanied by higher in-hospital mortality.
CONCLUSIONS: Syncope is a frequent cause for referrals in hospitals. While the overall in-hospital mortality rate is low (<2%), syncope in coprevalence with PE, pneumonia, MI and stroke showed a mortality rate > 8%. Syncope in AF patients had no independent impact on in-hospital mortality.
PMID: 30770163 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - February 13, 2019 Category: Internal Medicine Authors: Keller K, Hobohm L, Münzel T, Ostad MA Tags: Eur J Intern Med Source Type: research
Stroke prevention in patients with acute ischemic stroke and atrial fibrillation in Germany - a cross sectional survey
Atrial fibrillation (AF) is present in 15 –20% of patients with acute ischemic stroke. Oral anticoagulation reduces the risk of AF-related recurrent stroke but clinical guideline recommendations are rather vagu...
Source: BMC Neurology - February 12, 2019 Category: Neurology Authors: Alexander Wutzler, Christos Krogias, Anna Grau, Roland Veltkamp, Peter U. Heuschmann and Karl Georg Haeusler Tags: Research article Source Type: research
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
This study details the design of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study – a postauthorization observational study, which is part of the postapproval plan for edoxaban agreed with the European Medicines Agency.
Methods
The ETNA-AF-Europe study (Clinicaltrials.gov: NCT02944019) is a multicenter, prospective, observational study that enrolled 13 980 patients with atrial fibrillation treated with edoxaban from 852 sites across 10 European countries (Austria, Belgium, Germany, Ireland, Italy, the Netherlands, Portugal, Spain, Switzerland,...
Source: Journal of Cardiovascular Medicine - January 3, 2019 Category: Cardiology Tags: Research articles: Trial design Source Type: research
Impact of atrial fibrillation on in-hospital mortality of ischemic stroke patients and identification of promoting factors of atrial thrombi – Results from the German nationwide inpatient sample and a single-center retrospective cohort
Ischemic stroke is one of the leading causes of death and disability. Atrial fibrillation (AF) is a well-recognized risk factor for ischemic stroke.
We aimed to investigate the impact of AF on in-hospital mortality of ischemic stroke patients and to identify parameters associated with intra-cardiac thrombogenic material.
Patients were selected by screening the nationwide sample for ischemic stroke by ICD-Code (I63), stratified for AF. In this cohort, the association between in-hospital deaths and AF was investigated.
In a second study, we performed a retrospective analysis of patients who underwent transesophageal echoc...
Source: Medicine - January 1, 2019 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Impact of dronedarone on the risk of myocardial infarction and stroke in atrial fibrillation patients followed in general practices in Germany
The goal of this study was to analyze the impact of dronedarone on the risk of myocardial infarction and stroke in atrial fibrillation (AF) patients followed in general practices in Germany.
Source: International Journal of Cardiology - December 1, 2018 Category: Cardiology Authors: Joachim R. Ehrlich, Christiane Look, Karel Kostev, Carsten W. Israel, Andreas Goette Source Type: research
NOAC Therapy Is Also Effective and Safe in Patients Older Than 80 Years -- Results of the Prospective Dresden NOAC Registry (NCT01588119)
Conclusions: During long-term FU of more than 2.5 years, this very old population of NOAC recipients demonstrated low rates of cardiovascular or major bleeding complications during active NOAC therapy. Approximately one quarter of the study population died during follow-up, with cardiovascular events being the leading cause of death. Only 11 fatal bleeding events were observed; however, most of the 58 fatal thromboembolic events occurred after anticoagulation was discontinued. This indicates that continued anticoagulation with NOACs may result in a beneficial risk-benefit ratio also in very old patients.DisclosuresBeyer-We...
Source: Blood - November 21, 2018 Category: Hematology Authors: Beyer-Westendorf, J., Tittl, L., Naue, C., Marten, S. Tags: 332. Antithrombotic Therapy: Management of Challenging Patients and Scenarios Source Type: research
Certification criteria for stroke units in Germany : Update 2018.
This article describes the revised criteria for certified stroke units (SU) in Germany that will apply from 1 October 2018. Due to the high level of quality only minor adjustments and specifications were necessary in many places and the majority of criteria remained unchanged. For the first time a uniform personnel quota of ≥1.75 full-time staff per monitor bed is defined, which is a better reflection of the treatment reality. The evidence-based process of acute vascular imaging using computed tomography angiography (CTA) and alternatively magnetic resonance angiography (MRA) is now defined as a minimum rate of≥20 % ...
Source: Der Nervenarzt - October 29, 2018 Category: Neurology Authors: Nabavi DG, Koennecke HC, Ossenbrink M, Grau A, Busse O, die Stroke Unit Kommission, den Zertifizierungsausschuss der DSG, den Vorstand der DSG, den Zertifizierungsausschuss der DSG Tags: Nervenarzt Source Type: research
Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study.
CONCLUSION: This study demonstrated that using apixaban instead of VKA for stroke prevention can lead to considerable reduction in cardiovascular events.
PMID: 30295561 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 10, 2018 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
External validation of the A2DS2 and ISAN scales for predicting infectious respiratory complications of ischaemic stroke
ConclusionHigh scores on A2DS2 and ISAN were found to be a strong predictor of respiratory infection associated with acute stroke in a cohort of consecutive patients with stroke. These easy-to-use scales are promising tools for predicting this complication in routine clinical practice.ResumenAntecedentes y objetivoLa neumonía asociada al ictus es una complicación relacionada con mal pronóstico. Las escalas A2DS2 e ISAN se han desarrollado recientemente por un grupo alemán e inglés, respectivamente, para predecir la neumonía intrahospitalaria tras un ictus agudo. Realizamos una validación externa de estas escalas en ...
Source: Neurologia - October 5, 2018 Category: Neurology Source Type: research
Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation
ConclusionsWith rivaroxaban, no significant differences were observed compared to phenprocoumon with regard to hospitalized bleedings or ischemic strokes. Dabigatran was associated with fewer bleedings and a similar risk of ischemic strokes compared to phenprocoumon. Apixaban was also associated with fewer bleedings but was unexpectedly associated with more ischemic strokes, possibly reflecting selective prescribing. The association of rivaroxaban with higher all-cause mortality unrelated to bleedings or strokes has been described previously but remains to be explained.
Source: European Journal of Clinical Pharmacology - October 1, 2018 Category: Drugs & Pharmacology Source Type: research
Expert opinion paper on atrial fibrillation detection after ischemic stroke
AbstractThis expert opinion paper on atrial fibrillation detection after ischemic stroke includes a statement of the “Heart and Brain” consortium of the German Cardiac Society and the German Stroke Society. This paper was endorsed by the Stroke Unit-Commission of the German Stroke Society and the German Atrial Fibrillation NETwork. In patients with ischemic stroke, detection of atrial fibrillation should usual ly lead to a change in secondary stroke prevention, since oral anticoagulation is superior to antiplatelet drugs. The detection of previously undiagnosed atrial fibrillation can be improved in patients with ische...
Source: Clinical Research in Cardiology - October 1, 2018 Category: Cardiology Source Type: research
Anticoagulant plus antiplatelet therapy for atrial fibrillation : Cost-utility of combination therapy with non-vitamin K oral anticoagulants vs. warfarin.
CONCLUSION: The derived ICER was 13,168.50 € per QALY, consistent with NOACs being cost-effective vs. warfarin when anticoagulation is used with antiplatelet agents. Nevertheless, country-, practice-, and patient-related factors influence the ICER. Our cost-utility calculation should be used a starting point for decision-making.
PMID: 30209519 [PubMed - as supplied by publisher]
Source: Herz - September 15, 2018 Category: Cardiology Tags: Herz Source Type: research
ARRIVE, ASCEND and the Future of Aspirin
“An aspirin a day keeps the doctor away,” an age-old adage revised to support stroke prevention, may no longer be relevant in light of new data presented at the European Society of Cardiology (ESC) Scientific Congress 2018 in Munich, Germany. Of course we have known for some time—and data cont inue to support us—that aspirin is highly effective in secondary prevention of cardiovascular disease (ie, in patients who have already had an adverse vascular event).
Source: ConsultantLive - September 6, 2018 Category: Internal Medicine Authors: Payal Kohli, MD Tags: Atrial Fibrillation Source Type: news
Patients ’ Priorities for Oral Anticoagulation Therapy in Non-valvular Atrial Fibrillation: a Multi-criteria Decision Analysis
DiscussionAlthough the relative impact of convenience on therapy value is small, patients have different preferences for options within convenience criteria. Besides considerations on safety and effectiveness, physicians should also discuss attributes of convenience with patients, as it can be assumed that alignment to patient preferences in drug prescription and better patient education could result in higher adherence.
Source: American Journal of Cardiovascular Drugs - August 22, 2018 Category: Cardiology Source Type: research
